Gradalis

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Gradalis sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Gradalis: 13 sponsored US clinical trials, none currently recruiting.

Gradalis sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ewing's Sarcoma, with 2 trials.

Top-decile sponsor footprint

Gradalis ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

9 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Trial of Vigil for Participants With Ovarian Cancer

NCT02346747
TERMINATED Phase 3

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
COMPLETED Phase 2

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

NCT03073525
COMPLETED Phase 1

Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma

NCT02736565
COMPLETED Phase 2

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

NCT02511132
COMPLETED Phase 1

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

NCT02574533
COMPLETED Phase 2

Salvage Ovarian FANG™ Vaccine + Carboplatinum

NCT01867086
COMPLETED Phase 2

Salvage Ovarian FANG™ Vaccine + Bevacizumab

NCT01551745
TERMINATED Phase 2

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

NCT01505166
COMPLETED Phase 1

Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

NCT01505153
TERMINATED Phase 2

Phase II FANG™ in Advanced Melanoma

NCT01453361
COMPLETED Phase 2

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

NCT01309230
COMPLETED Phase 1

Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

NCT01061840

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 8
Phase 3 1

Therapeutic Areas

Ewing's Sarcoma 2
Melanoma Recurrent 1
Stage III Ovarian Cancer 1
Liver Cancer 1
Malignant Melanoma 1
Stage IV Ovarian Cancer 1
Ovarian Neoplasms 1
Melanoma 1
Non-Small Cell Lung Cancer 1
Ovarian Cancer 1

How the Gradalis early-phase archive is shaped

13 indexed studies, none listed as recruiting (0% open); 9 completed (69%).

Phase mix: 1 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Ewing's Sarcoma (2 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Gradalis: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Gradalis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share GradalisAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
Gradalis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gradalis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Gradalis page

13 registered trials is a research-attention snapshot, not an endorsement of Gradalis or any single study.

  • None of Gradalis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Ewing's Sarcoma is the condition Gradalis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ewing's Sarcoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Gradalis pipeline card: 13 registered trials from official public datasets.Report a data error.